SLS009
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SLS009, covering 2026-03-16 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML [Phase 1, Phase 2]